Objective To evaluate the efficacy and safety of non-overload dose of tegrilol before elective percutaneous coronary intervention(PCI) in patients with acute coronary syndrome(ACS). Methods Prospectively selected ACS patients scheduled for PCI were randomly divided into experimental group(148 cases) and control group(139 cases). The experimental group was given tegrilol 90 mg for the first time and then maintained 90 mg twice a day. The difference was that the control group was given tegrilol 180 mg loading dose for the first time, and the rest were given standard drug treatment for coronary heart disease. The incidence of major cardiovascular and cerebrovascular adverse events(MACCE) and hemorrhage during hospitalization and 1 year after operation were observed.Results Compared with the control group, there was no significant difference in the incidence of major adverse cardiovascular and cerebrovascular events and hemorrhagic events during hospitalization and 1 year after operation between the experimental group and the control group(P>0.05). Conclusion For patients with acute coronary syndrome with low or medium risk of ischemia, the therapeutic effect of loading dose tegrilo group before PCI is basically the same as that of non-using group, and the incidence of bleeding is similar.
Delayed percutaneous coronary intervention